AR132404A1 - Compuestos dirigidos a steap2 y uso de los mismos - Google Patents

Compuestos dirigidos a steap2 y uso de los mismos

Info

Publication number
AR132404A1
AR132404A1 ARP240100916A ARP240100916A AR132404A1 AR 132404 A1 AR132404 A1 AR 132404A1 AR P240100916 A ARP240100916 A AR P240100916A AR P240100916 A ARP240100916 A AR P240100916A AR 132404 A1 AR132404 A1 AR 132404A1
Authority
AR
Argentina
Prior art keywords
compounds
steap2
pharmaceutically acceptable
acceptable salts
present disclosure
Prior art date
Application number
ARP240100916A
Other languages
English (en)
Inventor
Vanessa Marie Muniz-Medina
Jeong Min Han
Frank Irvine Comer
Dyk Dewald Van
Darlene Anne Monlish
Saleemulla Mahammad
Nathanael David Sallada
Sao Fong Cheung
Asurayya Worrede
Chien Chang
- Rodriguez Caicedo David Ying
William Leslie Turnbull
Original Assignee
Astrazeneca Uk Ltd
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd, Fusion Pharmaceuticals Inc filed Critical Astrazeneca Uk Ltd
Publication of AR132404A1 publication Critical patent/AR132404A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona compuestos o sales farmacéuticamente aceptables de los mismos, por ejemplo, radioinmunoconjugados que incluyen una porción quelante o un complejo metálico de la misma, un ligador y un anticuerpo o fragmento de unión a antígeno del mismo que se dirige a STEAP2. La presente divulgación también proporciona composiciones farmacéuticas de estos compuestos o sales farmacéuticamente aceptables de los mismos y métodos de tratamiento para condiciones, por ejemplo, cáncer, usando estos compuestos, sales farmacéuticamente aceptables de los mismos o composiciones farmacéuticas.
ARP240100916A 2023-04-12 2024-04-11 Compuestos dirigidos a steap2 y uso de los mismos AR132404A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363495561P 2023-04-12 2023-04-12

Publications (1)

Publication Number Publication Date
AR132404A1 true AR132404A1 (es) 2025-06-25

Family

ID=91076806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100916A AR132404A1 (es) 2023-04-12 2024-04-11 Compuestos dirigidos a steap2 y uso de los mismos

Country Status (14)

Country Link
US (1) US20240350682A1 (es)
EP (1) EP4694940A1 (es)
JP (1) JP2026515739A (es)
KR (1) KR20250168673A (es)
CN (1) CN120936390A (es)
AR (1) AR132404A1 (es)
AU (1) AU2024250505A1 (es)
CL (1) CL2025003080A1 (es)
CO (1) CO2025015456A2 (es)
CR (1) CR20250479A (es)
IL (1) IL323857A (es)
MX (1) MX2025012115A (es)
TW (1) TW202506205A (es)
WO (1) WO2024215948A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
MX387295B (es) 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
DE102016114470A1 (de) 2016-08-04 2018-02-08 Landscaper Service & Design Gmbh Flexibler Schüttgutbehälter
KR102520731B1 (ko) * 2016-09-23 2023-04-14 리제너론 파아마슈티컬스, 인크. 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도
IL312003A (en) * 2021-10-15 2024-06-01 Astrazeneca Ab Chimeric ANTI-STEAP2 receptors and their uses

Also Published As

Publication number Publication date
TW202506205A (zh) 2025-02-16
EP4694940A1 (en) 2026-02-18
JP2026515739A (ja) 2026-05-19
CR20250479A (es) 2026-05-26
CN120936390A (zh) 2025-11-11
MX2025012115A (es) 2025-11-03
CL2025003080A1 (es) 2026-01-16
AU2024250505A1 (en) 2025-11-27
KR20250168673A (ko) 2025-12-02
IL323857A (en) 2025-12-01
CO2025015456A2 (es) 2025-11-19
US20240350682A1 (en) 2024-10-24
WO2024215948A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
UY38700A (es) Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
MX2021002804A (es) Terapias de combinacion.
MX2024008551A (es) Terapias de combinacion.
PE20241582A1 (es) Anticuerpos lrrc15 y conjugaddos de los mismos
PE20211412A1 (es) Anticuerpos anti-gdf15, composiciones y metodos de uso
MX2020011868A (es) Inhibidores de los receptores erbb.
CL2024002658A1 (es) Moléculas de unión contra fralfa
MX2020007947A (es) Inhibidores de erbb/btk.
MX2022004582A (es) Anticuerpo humanizado marcado con ri.
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
DOP2024000245A (es) Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos
MX2022001133A (es) Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
AR129382A1 (es) Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso
CO2024003299A2 (es) Conjugado anticuerpo-fármaco anti-cd37
CO2026002111A2 (es) Anticuerpos gucy2c y usos de estos
DOP2025000285A (es) Inhibidores de ciclina
CO2021017477A2 (es) Terapia de combinación
MX2025012115A (es) Compuestos dirigidos al antigeno epitelial de seis transmembranas de la prostata 2 (steap2) y uso de los mismos
AR122411A1 (es) Radioinmunoconjugados dirigidos a tem-1 y sus usos
CL2022002557A1 (es) Radioinmunoconjugados dirigidos a fgfr3 y usos de estos
CL2024001656A1 (es) Conjugado que comprende amatoxina y un resto de unión a cd20.
UY39662A (es) Inhibidores de egfr
PY24103378A (es) Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
CL2025001474A1 (es) Anticuerpos anti-cd137 y métodos de uso
AR122660A2 (es) Anticuerpos anti-pmel17 y conjugados de los mismos